Devazepide

Devazepide (L-364,718) 是一种有效、竞争性、选择性和口服活性的胆囊收缩素 (CCK) 受体非肽拮抗剂，对大鼠胰腺、牛胆囊和豚鼠脑 CCK 受体的 IC50 分别为 81 pM、45 pM 和 245 nM .

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1625.00

1300.00

- +
10mg

￥2725.00

2180.00

- +
25mg

￥4850.00

3880.00

- +
50mg

￥7012.00

5610.00

- +
100mg

￥10250.00

8200.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci20520
CAS: 103420-77-5
别名: 地伐西匹; L-364,718; MK-329
分子式: C25H20N4O2
分子量: 408.46
纯度: >98%
溶解度: <40.85mg/ml in DMSO; <20.42mg/ml in ethanol
储存: Store at -20°C, sealed storage, away from moisture and light
库存: 现货

Background

Devazepide is a potent CCK-A receptor antagonist with IC50 of 0.26 nM. [1]

Cholecystokinin (CCK) has long been recognized as the dominant regulator of gallbladder contraction. The cholecystokinetic activity of different fragments of CCK in human has been established in several studies both in vivo and in vitro. There are two subtypes of CCK receptor that were identified, CCK-A and CCK-B. CCK-A are mainly located in peripheral tissues but also found in brain, while CCK-B distribute throughout the rodent central nervous system.

Devazeptide inhibitory effect against sulphated C-terminal octapeptide of cholecystokinin (CCK-8) on total [3H] inositol phosphate accumulation in CHO-AI cells was investigated. The results revealed that devazepide possesses an inhibitory effect with IC50 of 0.26 ± 0.06 nM. CCK-8 is considered to be the most potent endogenous anti-opiate agent. Morphine analgesia could be antagonized by treatment of CCK-8. However, the effect of CCK-8 could be reversed by devazeptide which could also potentiate analgesia of morphine greatly at doses of 50ng and 200ng. [2, 3]

Devazepide is a benzodiazepine derivative that interacts competitively with rat pancreatic CCK receptors as determined by Scatchard analysis against the specific binding of 125I-labelled CCK. In guinea-pig isolated ileum and colon, devazepide competitively blocked CCK-induced contractions with a potency greatly exceeding that of other non-peptide CCK antagonists such as proglumide, dibutyryl cyclic GMP and benzotript. It is confirmed that devazepide is a highly potent CCK-OP antagonist in this tissue. [4]

参考文献:
[1] Dickenson, John M.?, and Stephen J. Hill. "Synergistic interactions between human transfected adenosine A 1 receptors and endogenous cholecystokinin receptors in CHO cells."?European journal of pharmacology?302.1 (1996): 141-151.
[2] Lavigne, G.? J., W. R. Millington, and G. P. Mueller. "The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment."Neuropeptides?21.2 (1992): 119-129.
[3] Pu, Su-Fen, Hui-Xin Zhuang, and Ji-Sheng Han.? "Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor."?Brain research?657.1 (1994): 159-164.
[4] D'amato, M.?, I. F. Stamford, and A. Bennett. "Studies of three non‐peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea‐pig ileum."?British journal of pharmacology?102.2 (1991): 391-395.